New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24161316.
- Also identified by DOI 10.1016/j.jacc.2013.08.1639 and PMC identifier 5928500.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Calcific aortic valve stenosis (CAVS) is the most common form of acquired valvular heart disease, present in 3% of the population more than 75 years of age (1). Although risk factors are similar for CAVS and atherosclerosis, ~50% of patients with CAVS do not have clinically significant cardiovascular disease (CVD), suggesting related, but unique, pathophysiology (1). Although surgical aortic valve replacement remains the gold standard treatment for most patients, at least one-third of symptomatic patients with CAVS may not undergo surgical aortic valve replacement.
Medical subject headings
- 1-Alkyl-2-acetylglycerophosphocholine Esterase
- Aortic Valve
- Aortic Valve Stenosis
- Calcinosis
- Gene Expression Regulation
- Heart Defects, Congenital
- Heart Valve Diseases
- Hyperlipoproteinemias
- Lipoprotein(a)
- Population Surveillance
- RNA, Messenger
- Risk Assessment